



**STEM CELL SOCIETY**  
SINGAPORE

# STEM CELL SOCIETY SEMINAR

**2 November 2012, Friday, Discovery Theatrette, Matrix Building Level 4**  
30 Biopolis Street, Singapore 138671

## PROGRAMME

**4.30 - 5.30pm**

**Dr Michael MAY**

CEO, Centre for Commercialization of Regenerative Medicine (CCRM)

**"Building Public-Private Collaboration in Regenerative Medicine: a Canadian Perspective"**

**5.30pm onwards**

**Network Social (brought to you by High Commission of Canada)**

**Hosted by**

**Huck Hui NG**

President, Stem Cell Society and ED, Genome Institute of Singapore



# SPEAKER

**Dr. Michael MAY, CEO, CCRM**

## **Building Public-Private Collaborations in Regenerative Medicine: a Canadian Perspective**

### **Abstract**

The Centre for Commercialization of Regenerative Medicine (CCRM) is a Canadian not-for-profit, public-private consortium funded by the Government of Canada's Networks of Centres of Excellence program, six Ontario-based institutional partners and more than 20 leading companies in regenerative medicine industry. CCRM supports the development of technologies that accelerate the commercialization of stem cell- and biomaterials-based technologies and therapies. The office, located at the Banting Institute at the University of Toronto, has a 7,000 square foot development facility that houses three platforms: Cell Reprogramming and Engineering; Cell Manufacturing; and, Biomaterials and Devices. A network of academics, industry and entrepreneurs, CCRM translates scientific discoveries into marketable products for patients. CCRM launched in Toronto's Discovery District on June 14, 2011. Partnering with industry completes the puzzle, capturing business expertise to accelerate product development and commercialization.

CCRM's industry consortium represents the key sectors of the regenerative medicine industry: therapeutics, devices, reagents, and cells as tools.

In his presentation, Michael May will share initial experiences from CCRM's first year and demonstrate what CCRM brings to the international community. He will also discuss how CCRM, as a Technology Innovation Centre (TIC), will support and drive the commercialization of cell therapies. How will the gap between the public and private sectors be bridged? How can CCRM de-risk the development of stem cell therapies for industry? What does the future hold for a vibrant, innovative industry, centred on a technology innovation centre like CCRM? How might CCRM work at a national level and also collaborate internationally? What might be the knock on effect for the Australasian stem cell therapy industry in terms of driving forward therapies that are economically and clinically good choices?

### **Biography**

Michael May is currently the Chief Executive Officer of the Centre for Commercialization of Regenerative Medicine (CCRM) a Canadian, federally incorporated, not-for-profit organization dedicated to supporting the development of foundational technologies that accelerate the commercialization of stem cell – and biomaterials – based technologies. Prior to CCRM, Michael was the President, and co-founder of Rimon Therapeutics Ltd., a Toronto-based regenerative medicine company developing novel medical polymers that possess drug-like activity. Dr. May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship in recognition of company creation from academic discovery.

Michael sits on a number of Boards and advisory committees including: MaRS Innovation, 20/20 Vision a centre of excellence for biomaterials in ophthalmology, the Biozone and Bioproducts + Enzymes from Environmental Metagenomes Commercialization Committee and the Department of Chemical Engineering and Applied Chemistry, at the University of Toronto.